Rockeby says test can also apply to children
19 October, 2004 by Renate KrelleRockeby's (ASX:RBY) laboratory-based SysCan tests for Candida antibody levels is likely to be useful for diagnosing the infection in children, a trial in Singapore has found.
Prana heading for the clinic
19 October, 2004 by Graeme O'NeillMelbourne brain-drug developer Prana Biotechnology (ASX:PBT, NASDAQ:PRAN) will move its is lead Alzheimer's disease drug PBT-1 (clioquinol) into a Phase II/III clinical trial in the first half of next year, with the aim of carving up to three years from the time required to deliver the drug to the clinic.
Eqitx vaccine research results published
18 October, 2004 by Graeme O'NeillA research paper in the prestigious US journal Proceedings of the National Academy of Science this week has underscored the commercial potential of the platform vaccine technology being commercialised by Eqitx (ASX:EQX) subsidiary VacTX, the company has claimed.
Burrill honours biotech's 'best of 2004'
18 October, 2004 by Staff WritersSan Francisco-based biotechnology investment bank Burrill & Co has named its 'best of biotech' for 2004.
Bionomics names new chairman
18 October, 2004 by Renate KrelleBionomics (ASX:BNO) has appointed former Reserve Bank economist Dr Peter Jonson as chairman, and extended the contract of chief executive officer and managing director Dr Deborah Rathjen until June 2008.
New player Gateway aims to fill commercialisation gap
15 October, 2004 by Renate KrellePerth-based biotech project management company Gateway Capital is about to step into the ring with venture capital players and investment banks, announcing today it will aim to fast-track biotech research from research institute to ASX.
Agenix sets up deal with US firm Inverness
15 October, 2004 by Melissa TrudingerAgenix (ASX:AGX) subsidiary AGEN Biomedical has secured a manufacturing and technology transfer alliance with US company Inverness Medical Innovations for its animal health diagnostic products.
Cytopia to raise $13m in rights issue
13 October, 2004 by Melissa TrudingerCytopia (ASX:CYT) will raise AUD$13.2 million in a fully underwritten non-renounceable rights issue.
Tissue Therapies bolsters cash reserves
13 October, 2004 by Melissa TrudingerBrisbane company Tissue Therapies (ASX:TIS) has bolstered its cash reserves through a placement of $1.46 million before costs to institutional and sophisticated investors.
Living Cell tops up coffers with $4.8 million
13 October, 2004 by Renate KrelleAfter raising AUD$6.36 million in its IPO last month, Living Cell Technologies (ASX:LCT) has announced a successful AUD$4.8 million top-up of its cash reserves.
AusBiotech signs agreement with Indian counterpart
13 October, 2004 by Iain ScottBiotechnology industry association AusBiotech has signed a memorandum of understanding with its Indian counterpart, the Association of Biotechnology Led Enterprises (ABLE).
Prima subsidiary signs licence deal with AstraZeneca
12 October, 2004 by Renate KrelleHelmed by a new chairman and in the middle a AUD$5-10 million capital raising, Melbourne's Prima Biomed (ASX:PRR) has ticked the first of the boxes on its lengthy to-do list, announcing that its Arthron subsidiary has signed a non-exclusive license with AstraZeneca to validate its anti-inflammatory Fc receptor target.
Qualified success in Imugene trial
12 October, 2004 by Renate KrelleImugene (ASX:IMU) has claimed a qualified success after a trial to test the ability of its receptor mimic technology (RMT) to prevent post-weaning diarrhoea in piglets.
Benitec grants licence to US xeno firm Revivicor
12 October, 2004 by Graeme O'NeillBenitec (ASX:BLT) has granted a licence to US company Revivicor to use its patented RNAi-mediated gene-silencing technology for mammalian cells to develop transgenic pigs as a source of organ transplants for humans.
Peplin slumps as Allergan collaboration ends
11 October, 2004 by Melissa TrudingerPeplin's share price has dropped 30 per cent today (Monday) on heavy trading after the company announced late on Friday that its collaboration with Allergan was to be discontinued, and all rights for the development and commercialisation of the company's topical skin cancer drug, PEP005 Topical, as well as data and IP generated during the collaboration, are to be returned to the Brisbane-based company.
